A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. 2010

Daniella Rylander, and Hanna Iderberg, and Qin Li, and Andrzej Dekundy, and Jinlan Zhang, and Hao Li, and Ren Baishen, and Wojciech Danysz, and Erwan Bezard, and M Angela Cenci
Basal Ganglia Pathophysiology Unit, Department of Experimental Medical Science, Lund University, BMC F11, Lund, Sweden.

L-DOPA remains the gold-standard treatment for Parkinson's disease but causes motor fluctuations and dyskinesia. Metabotropic glutamate receptor type 5 (mGluR5) has been proposed as a target for antidyskinetic therapies. Here, we evaluate the effects of fenobam, a noncompetitive mGluR5 antagonist already tested in humans, using rodent and nonhuman primate models of Parkinson's disease. In both animal models, acute administration of fenobam attenuated the L-DOPA-induced abnormal involuntary movements (50-70% reduction at the doses of 30mg/kg in rats and 10mg/kg in monkeys). The effect consisted in a reduction of peak-dose dyskinesia, whereas the end-dose phase was not affected. Chronic administration of fenobam to previously drug-naïve animals (de novo treatment) attenuated the development of peak-dose dyskinesia without compromising the anti-parkinsonian effect of L-DOPA. In addition, fenobam prolonged the motor stimulant effect of L-DOPA. We conclude that fenobam acts similarly in rat and primate models of L-DOPA-induced dyskinesia and represents a good candidate for antidyskinetic treatment in Parkinson's disease.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008253 Macaca mulatta A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans. Chinese Rhesus Macaques,Macaca mulatta lasiota,Monkey, Rhesus,Rhesus Monkey,Rhesus Macaque,Chinese Rhesus Macaque,Macaca mulatta lasiotas,Macaque, Rhesus,Rhesus Macaque, Chinese,Rhesus Macaques,Rhesus Macaques, Chinese,Rhesus Monkeys
D008297 Male Males
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D005260 Female Females
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Daniella Rylander, and Hanna Iderberg, and Qin Li, and Andrzej Dekundy, and Jinlan Zhang, and Hao Li, and Ren Baishen, and Wojciech Danysz, and Erwan Bezard, and M Angela Cenci
January 2013, Journal of Parkinson's disease,
Daniella Rylander, and Hanna Iderberg, and Qin Li, and Andrzej Dekundy, and Jinlan Zhang, and Hao Li, and Ren Baishen, and Wojciech Danysz, and Erwan Bezard, and M Angela Cenci
October 2013, Biochemical pharmacology,
Daniella Rylander, and Hanna Iderberg, and Qin Li, and Andrzej Dekundy, and Jinlan Zhang, and Hao Li, and Ren Baishen, and Wojciech Danysz, and Erwan Bezard, and M Angela Cenci
July 1994, Brain research,
Daniella Rylander, and Hanna Iderberg, and Qin Li, and Andrzej Dekundy, and Jinlan Zhang, and Hao Li, and Ren Baishen, and Wojciech Danysz, and Erwan Bezard, and M Angela Cenci
November 2020, Brain sciences,
Daniella Rylander, and Hanna Iderberg, and Qin Li, and Andrzej Dekundy, and Jinlan Zhang, and Hao Li, and Ren Baishen, and Wojciech Danysz, and Erwan Bezard, and M Angela Cenci
September 2012, The European journal of neuroscience,
Daniella Rylander, and Hanna Iderberg, and Qin Li, and Andrzej Dekundy, and Jinlan Zhang, and Hao Li, and Ren Baishen, and Wojciech Danysz, and Erwan Bezard, and M Angela Cenci
May 2012, European journal of pharmacology,
Daniella Rylander, and Hanna Iderberg, and Qin Li, and Andrzej Dekundy, and Jinlan Zhang, and Hao Li, and Ren Baishen, and Wojciech Danysz, and Erwan Bezard, and M Angela Cenci
March 2004, Neurobiology of disease,
Daniella Rylander, and Hanna Iderberg, and Qin Li, and Andrzej Dekundy, and Jinlan Zhang, and Hao Li, and Ren Baishen, and Wojciech Danysz, and Erwan Bezard, and M Angela Cenci
March 1999, Neurology,
Daniella Rylander, and Hanna Iderberg, and Qin Li, and Andrzej Dekundy, and Jinlan Zhang, and Hao Li, and Ren Baishen, and Wojciech Danysz, and Erwan Bezard, and M Angela Cenci
March 2016, Biological psychiatry,
Daniella Rylander, and Hanna Iderberg, and Qin Li, and Andrzej Dekundy, and Jinlan Zhang, and Hao Li, and Ren Baishen, and Wojciech Danysz, and Erwan Bezard, and M Angela Cenci
April 2020, Pharmacological reports : PR,
Copied contents to your clipboard!